Drug intelligence / Profile preview

bifidobacterium quadruple live bacteria tablets

Development stage: Unknown
Lead developer: Hangzhou Grand Biologic Pharmaceutical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium quadruple live bacteria tablets is a probiotic combination therapy consisting of four live bacterial strains: *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. It is primarily used to treat intestinal dysbiosis and associated symptoms such as diarrhea, constipation, and indigestion. The mechanism of action involves the synergistic interaction of the four strains: *Bacillus cereus* acts as a facultative anaerobe that consumes oxygen, creating a favorable environment for the growth of the other three anaerobic or facultative anaerobic strains. This restoration of the intestinal microecology inhibits the proliferation of pathogenic bacteria and reduces the production of endotoxins. In clinical research, the tablets are being evaluated for their ability to improve infection control and prevent recurrence in patients with cirrhosis and spontaneous bacterial peritonitis (SBP) by stabilizing the gut-liver axis and reducing bacterial translocation.

Brand names: Beifeida
Other names: Bifidobacterium quadruple live tabletsBifidobacterium quadruple probiotics双歧杆菌四联活菌片

Beyond the preview

Go deeper on bifidobacterium quadruple live bacteria tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium quadruple live bacteria tablets.

Explore the full profile